[go: up one dir, main page]

WO1992006954A3 - Derives de pyrrolidine dione - Google Patents

Derives de pyrrolidine dione Download PDF

Info

Publication number
WO1992006954A3
WO1992006954A3 PCT/US1991/006483 US9106483W WO9206954A3 WO 1992006954 A3 WO1992006954 A3 WO 1992006954A3 US 9106483 W US9106483 W US 9106483W WO 9206954 A3 WO9206954 A3 WO 9206954A3
Authority
WO
WIPO (PCT)
Prior art keywords
dione derivatives
pyrrolidine dione
treatment
relates
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006483
Other languages
English (en)
Other versions
WO1992006954A2 (fr
Inventor
Banavara L Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to EP91917487A priority Critical patent/EP0553130B1/fr
Priority to JP3516047A priority patent/JPH0692367B2/ja
Priority to DE69116162T priority patent/DE69116162T2/de
Priority to FI931666A priority patent/FI931666A0/fi
Publication of WO1992006954A2 publication Critical patent/WO1992006954A2/fr
Publication of WO1992006954A3 publication Critical patent/WO1992006954A3/fr
Anticipated expiration legal-status Critical
Priority to GR960400326T priority patent/GR3018920T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Dérivés de pyrrolidine dione de la formule (I), (II) ou (III), dans lesquelles R, R?1, R3, R4, R5¿ et X sont définis ci-dessous. Ces composés sont des inhibiteurs de la réductase d'aldose et sont utiles dans le traitement des complications associées au diabète telles que la neuropathie, la néphropathie, la rétinopathie et la cataracte. Ladite invention concerne également des compositions contenant les composés susmentionnés et des méthodes d'utilisation desdites compositions dans le traitement desdites complications associées au diabète.
PCT/US1991/006483 1990-10-15 1991-09-13 Derives de pyrrolidine dione Ceased WO1992006954A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP91917487A EP0553130B1 (fr) 1990-10-15 1991-09-13 Derives de pyrrolidine dione
JP3516047A JPH0692367B2 (ja) 1990-10-15 1991-09-13 ピロリジンジオン誘導体
DE69116162T DE69116162T2 (de) 1990-10-15 1991-09-13 Pyrrolidin-dionderivate
FI931666A FI931666A0 (fi) 1990-10-15 1991-09-13 Pyrrolidindionderivat
GR960400326T GR3018920T3 (en) 1990-10-15 1996-02-07 Pyrrolidine dione derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59761490A 1990-10-15 1990-10-15
US597,614 1990-10-15

Publications (2)

Publication Number Publication Date
WO1992006954A2 WO1992006954A2 (fr) 1992-04-30
WO1992006954A3 true WO1992006954A3 (fr) 1992-08-06

Family

ID=24392236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006483 Ceased WO1992006954A2 (fr) 1990-10-15 1991-09-13 Derives de pyrrolidine dione

Country Status (12)

Country Link
EP (1) EP0553130B1 (fr)
JP (1) JPH0692367B2 (fr)
AT (1) ATE132486T1 (fr)
CA (1) CA2091566A1 (fr)
DE (1) DE69116162T2 (fr)
DK (1) DK0553130T3 (fr)
ES (1) ES2082232T3 (fr)
FI (1) FI931666A0 (fr)
GR (1) GR3018920T3 (fr)
IE (1) IE913554A1 (fr)
PT (1) PT99224A (fr)
WO (1) WO1992006954A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239487A1 (fr) * 1995-12-15 1997-06-26 Novo Nordisk A/S Nouveau procede
KR100526487B1 (ko) * 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
BR0211750A (pt) 2001-08-10 2004-10-13 Shionogi & Co Agente antiviral
CN104001078A (zh) * 2014-06-05 2014-08-27 青岛市城阳区人民医院 一种治疗糖尿病肾病的中药药剂及制备方法
CN107892666B (zh) * 2017-12-12 2021-10-15 吉林医药学院 一种5-苯基吡咯衍生物及其制备方法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 89, no. 7, 14 August 1978, (Columbus, Ohio, US) Sato Yasunobu et al: "Synthetic studies on cardiovascular agents. IV. Synthesis of fused dihydropyridine derivatives", page 570, abstract 59846w, & Yakugaku Zasshi 1978, 98(4), 448-65, see reg. no. 67044-08-0, 67044-09-1, 67044-10-4, 67044-11-5, 67044-12-6, 67044-13-7 and 67044-14-8 *
J. Med. Chem., vol. 34, no. 3, March 1991, B.L. Mylari et al.: "A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxo-pyrrole-4-carboxylate, and its congeners", pages 1011-1018, see the whole article *
J. Pharm. Pharmacol., vol. 17, 1965, A.H. Beckett et al: "Some pyrroline derivatives as potential antiinflammatory agents", pages 498-503, see compounds II *
Tetrahedron, vol. 40, no. 21, 1984, J.E. Baldwin et al.: "Gamma-lactam analogues of penicillanic and carbapenicillanic acids", pages 4513-4525, see compound 246 *

Also Published As

Publication number Publication date
JPH05507284A (ja) 1993-10-21
FI931666A7 (fi) 1993-04-14
ES2082232T3 (es) 1996-03-16
CA2091566A1 (fr) 1992-04-16
DK0553130T3 (da) 1996-02-05
ATE132486T1 (de) 1996-01-15
DE69116162D1 (de) 1996-02-15
DE69116162T2 (de) 1996-05-02
WO1992006954A2 (fr) 1992-04-30
IE913554A1 (en) 1992-04-22
PT99224A (pt) 1992-09-30
FI931666L (fi) 1993-04-14
JPH0692367B2 (ja) 1994-11-16
EP0553130A1 (fr) 1993-08-04
GR3018920T3 (en) 1996-05-31
EP0553130B1 (fr) 1996-01-03
FI931666A0 (fi) 1993-04-14

Similar Documents

Publication Publication Date Title
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
WO2001090071A3 (fr) Iminoazines substituees
CA2274464A1 (fr) Cetobenzamides s'utilisant comme inhibiteurs de la calpaine
AU4950993A (en) Combination of germicidal agents
RU94036448A (ru) Производные галантамина и фармацевтическая композиция
HK35386A (en) Spiro-quaternary ammonium halides and n-(2-pyrimidinyl) piperazinylalkylazaspiroalkanedione process
NZ332658A (en) Halo-substituted bis-indolylmaleimide derivatives and pharmaceutical compositions
AU4627097A (en) Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same
WO2002094020A8 (fr) Utilisation de derives de triazolopyrimidine en tant que microbicides pour la protection de materiel
GR3022079T3 (en) Preparation of substituted piperidines
EP0791582A4 (fr) Derives des esters de l'acide indole-2-carboxylique, et bactericides destines a l'agriculture et a l'horticulture contenant ceux-ci comme ingredients actifs
CA2385200A1 (fr) Derives 4-hydroxybiphenyl hydrazides
CA2218663A1 (fr) Derives de benzisoxazole et d'indazole utilises comme agents neuroleptiques
WO1992006954A3 (fr) Derives de pyrrolidine dione
AU1067195A (en) N-substituted azabicycloheptane derivatives used, for example, as neuroleptics
WO2000012480A3 (fr) 3-aryle-pyrazoles substitues
EP1121932A4 (fr) Medicaments pour maladies oculaires
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
WO2001010861A3 (fr) Heterocyclyl-2h-chromenes substitues
WO2000011951A3 (fr) Utilisation de derives de 5-amino-pyrazol pour lutter contre des micro-oranismes
WO1999048851A3 (fr) Procedes de preparation d'intermediaires
MY133140A (en) N-substituted azabicycloheptane derivatives, their preparation and use
WO2002010160A3 (fr) Heterocyclyl alkyl amino 1,3,5-triazines substituees
HU9600300D0 (en) Thiocarbamoyl derivatives using as antimicrobial agents and process for producing of these

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2091566

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991917487

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 931666

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991917487

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991917487

Country of ref document: EP